

1 Ethnic disparities in medication adherence?  
2 A systematic review examining the association between ethnicity and  
3 antidiabetic medication adherence

4

5

6 Rayah Asiri<sup>1,2¶</sup>, Adam Todd<sup>1¶</sup>, Anna Robinson<sup>1¶</sup>, Andy Husband<sup>1\*¶</sup>

7

8

9 <sup>1</sup>: School of Pharmacy, Newcastle University, Newcastle upon Tyne, United Kingdom

10 <sup>2</sup>: School of Pharmacy, King Khalid University, Abha, Saudi Arabia

11 \* Corresponding author:

12 E-mail: [andy.husband@newcastle.ac.uk](mailto:andy.husband@newcastle.ac.uk) [Andy Husband]

13

14 ¶: All authors contributed equally to this work.

15

## 16 Abstract

17 **Objectives:** Adherence to prescribed medication is an essential component of diabetes  
18 management to obtain optimal outcomes. Understanding the relationship between medication  
19 adherence and ethnicity is key in optimising treatment for all people with different chronic illnesses,  
20 including those with diabetes. The aim of this review is to examine whether the adherence to  
21 antidiabetic medications differed by ethnicity among people with diabetes.

22 **Methods:** A systematic review was conducted of studies reporting adherence to antidiabetic  
23 medication amongst people from different ethnic groups. MEDLINE, Embase, CINAHL, and PsycINFO  
24 were searched from their inception to June 2021 for quantitative studies with a specific focus on  
25 studies assessing adherence to antidiabetic medications (PROSPERO: CRD42021278392). The Joanna  
26 Briggs Institute critical appraisal checklist and a second checklist designed for studies using  
27 retrospective databases were used to assess study quality. A narrative synthesis approach was used  
28 to summarize the results based on the medication adherence measures.

29 **Results:** Of 15,685 citations screened, 39 studies that included observational retrospective  
30 database research and cross-sectional studies were selected, each of which involved diverse ethnic  
31 groups from different settings. This review identified a difference in the adherence to antidiabetic  
32 medications by ethnicity in 37 studies, despite adjustment for several confounding variables that may  
33 otherwise explain these differences.

34 **Conclusion:** This review revealed that adherence to antidiabetic medication differed by ethnicity.  
35 Further research is needed to explore the ethnicity-related factors that may provide an explanation  
36 for these disparities.

37

38

## 39 Introduction

40 Diabetes is a common and clinically significant metabolic disorder, and, in recent decades, has  
41 become a major medical burden, reaching the point of a global pandemic [1, 2]. In 2019, an estimated  
42 463 million people worldwide are thought to have diabetes [1], and this number is set to increase in  
43 the future: by 2045, the prevalence is estimated to reach 700 million globally [1, 3]. Furthermore,  
44 people with diabetes are at increased risk of developing microvascular (*e.g.*, ischemic heart disease  
45 and cerebrovascular disease) and macrovascular complications (*e.g.*, nephropathy and retinopathy)  
46 as well as having an increased risk of all-cause mortality [4-6]. Accordingly, glycemic control on a long-  
47 term basis is critical to diabetes management and good control has been shown to reduce diabetic  
48 complications [7, 8]. In conjunction with lifestyle management, such as diet and physical activity,  
49 improving adherence to antidiabetic medication is an important aspect of management to delay or  
50 prevent the associated complications [9]. Improving medication adherence is considered an integral  
51 part of any diabetes management plan for patients [10]. Adherence is defined as the extent to which  
52 patients follow their prescriber's instructions when taking medicines [11]. In 2003, the World Health  
53 Organization (WHO) reported that 'increasing the effectiveness of adherence interventions may have  
54 a far greater impact on the health of the population than any improvement in specific medical  
55 treatment'[12]. Improving adherence to diabetic medication is associated with improved glycemic  
56 control, reduced risk of hospitalization and mortality, as well as lower healthcare expenditure [13,  
57 14]. There are, however, many factors that affect adherence to diabetes medication, including  
58 disease-related (*e.g.*, the course of the illness and presence of other comorbid conditions) and  
59 treatment-related factors (complex therapy, adverse effects, and polypharmacy) [12, 15-17].

60 Moreover, such factors can also be influenced by information accessibility and transparency,  
61 community support, beliefs and attitudes towards a healthy lifestyle, the patient–healthcare provider  
62 relationship, mental health, and self-efficacy [18]. Furthermore, patient characteristics, such as  
63 socioeconomic background and cultural beliefs, also have potential to influence how people adhere  
64 to their medicines [12]. One such patient factor that has seldom been studied in this context is  
65 ethnicity. Given there is increased incidence of diabetes in certain ethnic groups [19], it is important  
66 to establish if, or how, adherence to diabetes medication varies by ethnic groups. This systematic  
67 review, therefore, aimed to explore whether medication adherence to antidiabetic medications in  
68 People with diabetes varied by ethnicity.

69

70

## 71 **Methods**

72 This systematic review was registered with PROSPERO (CRD42021278392) and conducted with the  
73 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (S1  
74 Table) [20].

### 75 **Search strategy and study selection**

76 A systematic and comprehensive literature search was conducted in the following electronic  
77 databases: MEDLINE, Embase, CINAHL, and PsycINFO; from inception to June 2021. No search  
78 restrictions were applied to the language or date of publication. Quantitative observational studies

79 and the quantitative sections of studies with mixed methods, examining adherence to antidiabetic  
80 medications according to ethnicity were eligible for inclusion.

81

82 The inclusion criteria of this review were conceptualized by the PICOS (Population, Intervention,  
83 Comparison, Outcome and Study Design) framework:

- 84 • *Population*: people from any ethnic groups with type 1 or type 2 diabetes mellitus.
- 85 • *Intervention*: insulin and/or other antidiabetic medication, including sulfonylureas,  
86 biguanides, meglitinide, thiazolidinedione, dipeptidyl peptidase-4 inhibitors, sodium- glucose  
87 cotransporter inhibitors,  $\alpha$ -glucosidase inhibitors, and glucagon-like peptide-1 receptors  
88 agonists.
- 89 • *Comparison*: people from any other ethnic groups with type 1 or type 2 diabetes mellitus.
- 90 • *Outcome*: Medication adherence or persistence, measured by any medication adherence  
91 measure (measures based on the data of electronic databases, self-reported measures, pill  
92 counts, electronic monitoring, and biomedical measures), reported according to ethnicity.
- 93 • *Study design*: quantitative observational and mixed method studies reporting on adherence  
94 by ethnicity.

95

96 The studies were required to measure adherence to antidiabetic therapy in more than one ethnic  
97 group. Any study only reporting adherence for one ethnic group only was excluded, as were studies  
98 that evaluated adherence to all medications used to control diabetes and other comorbid conditions.  
99 Qualitative studies, reviews, editorials, conference abstracts, and intervention studies were also  
100 excluded from the review.

101 To complement the database searches, a grey literature search was undertaken. The reference lists  
102 of all included studies were hand-searched for relevant papers not retrieved in the database search.  
103 The search strategy is described in [S1 Text](#). The initial screening of titles and abstracts was  
104 undertaken by one reviewer (RA), while full-text article screening was conducted by (RA) and checked  
105 in full by (AT or AKH). Any disagreement was resolved through discussion and consensus.

106

## 107 **Data extraction and quality appraisal**

108 One reviewer (RA) undertook the data extraction and was checked by another (AR). Data from each  
109 study in respect of intervention, population, outcomes, key findings, and study limitations were  
110 compiled *via* a customised data extraction form. Three reviewers (RA, AT, AKH) undertook quality  
111 assessment using two relevant tools: the Joanna Briggs Institute's critical appraisal tools for cross-  
112 sectional studies [21], and a checklist for medication adherence and persistence studies, using  
113 retrospective databases [22] , as no validated quality assessment tool was suitable for all  
114 observational studies.

115

## 116 **Analysis and synthesis**

117 Due to the heterogeneity of ethnic groups, and measures used for medication adherence across the  
118 included studies, meta-analysis to combine individual study results was not possible. A narrative  
119 synthesis approach was employed to synthesize the data [23]. The influence of ethnicity on  
120 adherence to antidiabetic therapy is described based on medication adherence measures used across  
121 the included studies: measuring adherence using electronic databases, self-reported measures, and  
122 pill counts.

123

## 124 **A note on reporting of the ethnicity data**

125 While some included studies use the term 'race', we prefer the term 'ethnicity', which is defined in  
126 this review according to Senior and Bhopal 'implies one or more of the following: shared origins or  
127 social background; shared culture and traditions that are distinctive, maintained between  
128 generations, and lead to a sense of identity and group; and a common language or religious tradition  
129 [24].

130

131

## 132 Results

### 133 Literature search and study characteristics

134 The initial electronic database searches identified 15,685 citations, and another 22 publications were  
135 found from reference lists, citation, and a grey literature search. Following the removal of duplicates,  
136 15,013 studies were reviewed for eligibility based on the title and abstract; from this, 152 studies  
137 were selected for a full-text review. After full text screening, 39 studies were included in this  
138 systematic review (Fig 1).

139

#### 140 Fig 1. PRISMA flow diagram of included studies

141

142 All articles were published between 2005 and 2020 and were conducted in nine countries: United  
143 States (n=25)[25-49] , New Zealand (n=3) [50-52], United Kingdom (n=2)[53, 54] , Canada (n=1)[55],  
144 Malaysia (n=3)[56-58], Singapore(n=2)[59, 60] ,Brazil (n=1)[61] , Qatar (n=1)[62] and United Arab  
145 Emirates (n=1)[63]. The majority of included studies were retrospective database studies [26-29, 31-  
146 55, 57, 59, 60, 64], while the remaining were cross-sectional studies [28, 56, 58, 61-63]. The sample  
147 sizes ranged from 57[57] to 1,888,682 patients [37], and the mean age of patients ranged from 14 to  
148 71 years. Ethnicity was reported across studies as: ethnicity in (14 studies), race/ethnicity in (15  
149 studies), and race in (11 studies). The majority of studies examined adherence to antidiabetic  
150 medication among people with type 2 diabetes mellitus; only two studies examined adherence to  
151 antidiabetic medications for people with type 1 diabetes mellitus [57, 61]. Thirty studies used  
152 medication adherence measures based on the electronic database data: medication possession ratio,  
153 the proportion of days covered, or other measures centred on a pharmacy database. Of the

154 remaining nine studies, one used pill count to measure adherence [39], while eight used self-  
 155 reported measures of adherence [30, 47, 56, 58, 60-63]. Study characteristics are detailed in (Table  
 156 1).

157 Table 1. Study characteristics

Study (author/year)	Country	Study Design	Data source	Population (number, ethnicity data)	Antidiabetic medication	Medication adherence measure	Key finding
[51]	New Zealand	Retrospective database	Data collected from 10 general practices in the Waikato region.	N= 1595 New Zealand European. Maori. Asian. Pasifika. Others.	Metformin	MPR	Māori and Pasifika patients had poorer metformin adherence than patients of other ethnicities.  After adjusted analysis, the difference remained Māori compared to New Zealand Europeans (OR 0.41; 95% CI 0.30–0.56; P<0.001).
[35]	US	Retrospective database	Data from Kaiser Permanente Northern California.	N= 9923 White. Black. Hispanic. Asian. Other.	Insulin and/or OADs	PDC	Non-Hispanic Black (ARR, 1.52; 95% CI, 1.32–1.74), Hispanic (ARR, 1.28; 95% CI, 1.15–1.43), and Asian (ARR, 1.14; 95% CI, 1.01–1.29) women were more likely than non-Hispanic White women to be nonadherent.



[39]	US	Retrospective database	Data from DPP randomized clinical trial.	N=30445 White. Black. Hispanic. Other.	Metformin	Pill count	Odds of adherence was significantly lower for Black participants (HR 0.44; 95% CI 0.29 – 0.66; P<0.001) compared to Whites.
[50]	New Zealand	Retrospective database	The New Zealand Ministry of Health’s national data collections.	N=90,530 Māori Pacific European Asian Indian Middle Eastern/Latin American/African other and Unknown	Metformin	MPR	After adjusting for all the person- and health-related factors, the annual MPR for Māori (MPR -0.08 ,95% CI - 0.08 to 0.07) and Pacific (MPR-0.09 ,95% CI -0.10 to 0.08) peoples were lower than Europeans.
[56]	Malaysia	Cross-sectional	-	N=232 Malay Chinese Indian others	Insulin and/or OADs	Validated Medication Compliance Questionnaire	Malay patients had 1.43 times higher odds of nonadherence to medications than Chinese and Indian patients (95% CI 1.32–1.74; p=0.031).

[52]	New Zealand	Retrospective database	Pharmaceutical Collection Database maintained by the New Zealand's Ministry of Health.	N= 7138 New Zealand (NZ) European. Other European NZ Māori Indian	OHAs	PDC	Adherence was significantly higher in the NZ European ethnic group (PDC 64.4 vs. 9.1,20.1, and 2.8; P < 0.001).  Non-adherence was significantly higher in patients in New Zealand Māori patients (PDC 33.3 vs. 48.3,7.6, and 4.8; P < 0.001).
[36]	US	Retrospective database	Longitudinal claims data from a large US-based insurance provider	N=56720 White Asian Black Hispanic	OADs	PDC	Average adherence rates of blacks and Hispanics were 4.8 to 6.5 percentage points lower than whites (p <0.01).
[58]	Malaysia	Cross-sectional	-	N= 497 Malay. Indian. Chinese	OADs	MMAS	There was statistically significant association between ethnicity and medication adherence ( $X^2 = 10.660$ ; $P=0.031$ ).  The Indians had higher medication adherence compared with the Malays and the Chinese
[29]	US	Retrospective database	The Veterans Affairs electronic	N= 148,544 White	OADs	PDC	Except for Asians, all other minorities were less likely to be adherent compared with

			health records & outpatient pharmacy	African American Asian Native American Hawaiian/Pacific Islander			whites (OR = 0.62; 95% CI = 0.605-0.645).
[65]	UK	Retrospective database	Royal College of General Practitioners Research and Surveillance Centre database	N=60327 White Asian Black Mixed Other	OADs	CMG	Non-white ethnicity associated with reduced medication persistence compared to Whites (HR 1.53; 95%CI 1.47–1.59; P<0.001)
[62]	Qatar	Cross-sectional	-	N= 260 Arab Asian Other	Insulin and/or OADs	ARMS-D	Ethnicity was an independent predictor of adhere score (Beta -1.731; 95% CI -3.153 – 0.309; p=0.017). Arab ethnicity was likely to be non-adherent compared to Asian.
[28]	US	Retrospective database	Administrative claims data Hawaii	N= 5163 Japanese Native Hawaiians Whites Filipinos	OADs	PDC	After adjustment, Filipinos [OR=0.58, 95%CI (0.45,0.74)], Native Hawaiians [OR=0.74, 95%CI(0.56,0.98)], and people of other race [OR=0.67, 95%CI(0.55,0.82)]

				Chinese  Mixed race and  other race.			were significantly less  adherent to anti-diabetic  medications than Japanese
[60]	Singapore	Retrospective  database	Public primary  care clinic	N= 5163  Chinese  Malay  Indian  Other	OADs	MARS-5	Compared to Indian, patients  of Chinese ethnicity (OR  2.80; 95% CI 1.53–5.15;  P<0.01) had low adherence  to OADs.
[57]	Malaysia	Retrospective  database	Clinic  Paediatric at  University  Kembangan  Malaysia  Medical Centre	N=57  Malay  Chinese  Indian  Others	Insulin	MPR and  glycated  haemoglobin	Race was not associated with  adherence(p=1.000)
[40]	US	Retrospective  database	Administrative  claims data  from a large  health  insurance  company in  Hawaii	N= 30445  Japanese.  Filipino.  Chinese.  Caucasian.  Native Hawaiian.  Other Pacific  Islander.	Insulin  and/or  OADs	MPR	Native Hawaiians, Other  Pacific Islanders, and  Filipinos had significantly  lower adherence rates for  each medication compared  to other groups.

[59]	Singapore	Retrospective database	Multicentre data of the National Healthcare Group	N= 2463 Chinese Malay Indian Others	Insulin and/or OADs	PDC	Indian ethnicity (OR 0.59; 95% CI 0.48–0.73; P<0.001) was associated with poorer adherence compared with other ethnic groups in Singapore
[26]	US	Retrospective database	Kaiser Permanente Northern California Diabetes Registry	N= 30,838 White. Hispanic/Latino. African American. Asian.	Insulin and/or OADs	CMG	Latinos had greater non-adherence than white patients(p<0.05)
[33]	US	Retrospective database	Data from Kaiser Permanente Southern California	N= 23612 Non-Hispanic White Black Hispanic Asian or Pacific Islander Other/Unknown	OHAs	CMG	Black race (RR 1.28;95% CI 1.17 – 1.41), Hispanic ethnicity (RR 1.11 ;95% CI 1.03 – 1.20) were associated with discontinuation of one or dual OHAs.
[34]	US	Retrospective database	MarketScan Multi-State Medicaid Database	N= 1529 Caucasians	OADs	MPR	African Americans (OR 0.71; 95% CI 0.55–0.93; P<0.05) had significantly lower MPR than Caucasian patients.

				African Americans  Other races			
[61]	Brazil	Cross-sectional	-	N= 1698  Caucasian  Non-Caucasian	Insulin	Self-reported scales	Adherence to insulin was not related to ethnicity.
[41]	US	Retrospective database	Pennsylvania Medicaid administrative claims data	N= 16,256  White.  Black.  Hispanic.  Other/unknown.	OHAs	PDC	Compared to perfect adherers, enrollees who discontinued oral hypoglycaemics were non-white groups (43.3–57.3 % vs. 37.3 %; P<0.0001)
[63]	UAE	Cross-sectional	-	N= 446  Arab Emarati.  Arab Non-Emarati  Asian.	Insulin and/or OADs	MMAS	Adherence levels differed significantly between ethnic groups (p<0.001) with the lowest adherence levels for Emirati patients (81.6 %) followed by Arab Non-Emirati (47.1 %) and Asians (15.4 %).
[48]	US	Retrospective database	Group Health cooperative in Washington State and parts of Idaho	N= 509  White  African American	Insulin and/or OADs	MPR	Non-Hispanic were more likely to be non-adherent to diabetes medications compared to Hispanic.

				American Indian / Alaska Native.  Asian / Pacific Islander  Not Hispanic  Hispanic			
[30]	US	Cross-sectional	-	N= 7239  White  African American  Hispanic  Asian American  American Indian.	Insulin and/or antidiabetic drugs	MMAS	The White group had higher medication adherence (50.3%; P<0.001) compared to all groups except the American Indian group.
[55]	Canada	Retrospective database	Health administrative and pharmacy data from British Columbia	N=167243  White  South Asian  Chinese	Insulin and/or OADs	PDC	South-Asian (OR 0.44; 95% CI 0.41–0.47; P<0.0001) and Chinese people (OR 0.87; 95% CI 0.82–0.93; P<0.0001) had significantly lower adherence compared with white people.
[45]	US	Retrospective database	A Hawaiian health plan.	N=43445  White  Japanese  Chinese	Insulin and/or OADs	PDC	Filipinos, Native Hawaiians, and other Pacific Islanders were significantly less adherent than Whites(p<0.05).

				Filipino Native Hawaiian Other Pacific Islander			
[54]	UK	Retrospective database	Aggregated prescribing data of 76 General Practice surgeries within the Heart of Birmingham teaching Primary Care Trust	N= 23687 White Asian Black Mixed Other	OADs	MPR	There was a statistically significant variations in adherence between the major ethnic groupings. (MPR range from 86.8% for White groups to 58.3 % for Black groups)
[46]	US	Retrospective database	A large, Midwestern, integrated health system	N= 31636 White Black Asian Hispanic American Indian	Antidiabetic drugs	MPR	Non-White patients (OR 1.66 ; 95% CI 1.41 –1.95 ; P<0.001) have statistically significant lower adherence compared to the White
[38]	US	Retrospective database	Data from Kaiser	N= 12,061 Non-Hispanic White	Antidiabetic drugs	PDC	Patients of Hispanic ethnicity (OR 1.33; 95% CI 0.84–2.10) were more likely to be



			Permanente Colorado	Hispanic. Other.			primarily non-adherent compared to White.
[49]	US	Retrospective database	Texas Medicaid prescription claims data	N= 3109 White Black Hispanic Other	OADs	MPR	Race was statistically significantly related to adherence. The adherence was two times higher for whites compared to Hispanics (OR 2.02; 95% CI, 1.54 –2.66; P<0.0001).
[64]	US	Retrospective database	The National Patient Care &Pharmacy Benefits Management database	N= 690,968 NHW NHB Hispanic Other	Insulin and/or OHAs	MPR	Relative to non-Hispanic whites, MPR was significantly (6.07%) lower in non-Hispanic blacks, and (1.76%) Hispanics.
[42]	US	Retrospective database	Indiana Network of Patient Care	N= 3,976 White. African American	OADs	PDC	African American race were a significant risk factor for non-adherence compared to White race (OR 0.61; 95% CI 0.50 –0.73 ; P<0.001)
[43]	US	Retrospective database	Veterans Administration datasets	N= 11,272 NHW NHB Hispanic	Insulin and/or OHAs	MPR	NHB had statistically significantly lower MPR compared to NHW.

				Other			
[47]	US	Retrospective database	Two primary care clinics and two diabetes specialty clinics	N= 383 White African American	Antidiabetic drugs	SDSCA questionnaire	African American race was significantly associated with less medication adherence (r=-0.10, p<0.05)
[37]	US	Retrospective database	Administrative claims data primarily pharmacy claims data	N= 1,888,682 White Black Hispanic Others	OHAs	PDC	Black (OR 1.39; 95% CI 1.38 – 1.41; P<0.001) and Hispanic patients (OR 1.37; 95% CI 1.35–1.39; P<0.001) more likely than whites to be nonadherent.
[27]	US	Retrospective database	Harvard Vanguard Medical Associates electronic medical record system	N= 1906 Black White	Insulin and/or OADs	Monthly average rate of adherence	Blacks had statistically significantly lower MPR compared to Whites (IRR 0.79; 95% CI 0.63–0.99; P<0.05).
[31]	US	Retrospective database	Harvard Vanguard Medical Associates	N= 1806 Black White	OADs	Refill-based medication adherence	Black patients had a significant lower average of medication adherence compared to whites. (71.7% vs. 77.6%; P<0.0001)
[44]	US	Retrospective database	Data from the North Carolina	N= 17,685	OADs	MPR	The adherence rate of African American patients

			Medicaid program	African American. White			was significantly lower by 12% than whites (p<0.05)
[32]	US	Retrospective database	A large health care plan in Hawaii	N= 20685 Japanese Chinese Whites Hawaiians Filipinos other	OADs	MPR	Compared to Whites, Japanese patients (OR 1.20; 95% CI 1.0 –1.30) were the most likely to be adherent, followed by Chinese (OR 1.0; 95% CI 0.89 –1.20), Hawaiians (OR 0.89; 95% CI 0.77 –1.0), and Filipinos (OR 0.78; 95% CI 0.68 –0.90)

158 MPR: medication possession ratio, PDC: proportion of days covered, MMAS: Morisky Medication Adherence Scale, CMG:  
159 continuous single-interval measure of medication gaps, ARMS-D: Adherence to Refill and Medications Scale in Diabetes, MARS-  
160 5: five-question Medication Adherence Rating Scale, SDSCA: the Summary of Diabetes Self-Care Activities questionnaire, OHAs:  
161 oral hypoglycaemic agents, OADs: oral antidiabetic drugs ,NHW: Non-Hispanic Whites, NHB: Non-Hispanic Blacks, US: United  
162 State, UK: United Kingdom, OR: odd ratio, CI: confidence interval, ARR: adjusted risk ratio, P: p value, HR: hazard ratio, RR:  
163 relative risk, r:correlation coefficient, IRR: incidence rate ratio.

## 162 Quality assessment

163 Two quality assessment tools were used in this review based on the study design. The first tool, a  
164 checklist for medication adherence and persistence studies using retrospective databases, was used  
165 for the 33 retrospective database studies [22]. All study titles were descriptive and reflective of the  
166 study purpose, and all abstracts provided a short description of the work. The rationale and scientific  
167 background were reported in most studies except for five, which did not clearly state their objectives  
168 [26, 35, 42, 45, 57]. Most of the articles clearly stated the study design that matched the objectives;

169 only eight did not do so [36, 40, 47, 50-52, 54, 60] . The data sources were clearly defined in all  
170 studies; however, three papers did not state the time frame for data [26, 47, 59] . Of the 33 studies,  
171 29 clearly stated the eligibility criteria, but 16 did not explain the rationale for these criteria [26, 28,  
172 34, 39, 45, 47-49, 51, 52, 54, 55, 57, 60, 64] . The method of medication adherence measurement  
173 was clearly described in the majority of studies, but, for some studies, the method of handling the  
174 switching of drugs within and between therapeutic classes was not appropriately explained [26, 27,  
175 34, 38, 42-46, 48, 49, 52, 54, 55, 59, 60]. All studies apart from three [40, 41, 52], controlled the  
176 confounders, while all studies clearly presented their results and discussed the research implications  
177 (S2 Table).

178 The quality of the six remaining cross-sectional studies was assessed using the Joanna Briggs  
179 Institute’s critical appraisal tools for cross-sectional studies [21]. All studies clearly defined the  
180 inclusion criteria, study subjects, and settings, but two did not report on strategies to deal with  
181 confounding factors [30, 58]. All studies, but one, used a valid and reliable measure of medication  
182 adherence [61] (S3 Table).

183

## 184 **Narrative synthesis of the influence of ethnicity on adherence to** 185 **antidiabetic medication by method of measurement**

186

187 Studies were described below thematically according to medication adherence measures using a  
188 narrative synthesis approach [23].

### 189 **Studies measured adherence using electronic databases**

190 A variety of measures using pharmacy refill data were used to assess adherence to antidiabetic  
191 medications among different ethnic groups, including the MPR[28, 34, 40, 43, 44, 46, 48-51, 54, 57,  
192 60, 64], proportion of days covered[29, 35-38, 41, 42, 45, 52, 55, 59] , and other measures, such as

193 medication refill adherence and continuous single- or multiple-interval measures of medication  
194 gaps[26, 27, 31, 33, 53].

195

196 **Medication possession ratio:** Fourteen studies used the MPR to evaluate medication adherence for  
197 people with diabetes from different ethnic groups. Three studies assessed adherence to antidiabetic  
198 medications among the following ethnic groups: Japanese, Hawaiians, Whites, Filipinos, Chinese,  
199 mixed races, and other races [28, 40, 60] . The reported adherence rates varied by ethnicity with  
200 people of Japanese ethnicity most likely to be adherent to antidiabetic medications, followed by  
201 Whites, Chinese, Hawaiians, Filipinos, and other ethnic groups; this difference was statistically  
202 significant in two studies [28, 60]. The difference between people from the following ethnicities:  
203 Whites, African Americans, Hispanics, Asians, American Indians, and others in adherence to  
204 antidiabetic medications was also reported in seven studies [34, 43, 44, 46, 48, 49, 64]. People with  
205 a Non-White ethnicity had a statistically significant lower MPR compared to people with White  
206 ethnicity across these studies. Two other studies examined adherence to metformin among ethnic  
207 groups in New Zealand and revealed that people from Māori and Pacific ethnic groups had poorer  
208 adherence than people from the European group [50, 51] . Langley and colleagues also reported  
209 statistically significant variations in adherence to oral antidiabetic medications among different  
210 ethnic groups in the United Kingdom, with highest adherence rates reported for people from Irish  
211 ethnic groups, while lowest adherence rates were reported for people from African ethnic groups  
212 [54] . Only one study assessed adherence to insulin therapy for type 1 diabetes; across three Asian  
213 ethnic groups – Malay, Chinese, and Indian – ethnicity was not associated with adherence [57].

214

215 **Proportion of days covered:** Eleven studies used the proportion of days covered to assess adherence  
216 to antidiabetic medications by people of different ethnic groups. Of these, seven studies indicated  
217 that people from Black, Hispanic, and Asian ethnicity were more likely to be non-adherent to  
218 antidiabetic medications, and these findings were statistically significant in four studies [35-38, 41,  
219 42] . The adherence levels also differed among people with White, Chinese, Black, Hawaiian,  
220 Japanese, Filipino, and Native American ethnicities [29, 45, 55] . In contrast to the studies using the

221 MPR, one study found that the medication adherence of people from Chinese and Japanese ethnic  
222 groups did not differ significantly from people from White ethnicity; however, members of other  
223 ethnic groups were found to be significantly less adherent compared to people from White ethnic  
224 groups[45]. Additionally, significant differences in adherence to antidiabetic agents were reported  
225 among three Asian ethnic groups in a study conducted in Singapore, in which people from Indian  
226 ethnic groups had the lowest adherence rates compared to people from Malay or Chinese ethnic  
227 groups [59]. Lastly, Kharjul and colleagues reported a significantly higher rate of non-adherence  
228 among people from Māori ethnicity compared to other ethnic groups in New Zealand, which is  
229 consistent with the findings of studies assessing the same groups, using the MPR as a measure of  
230 adherence [52].

231

232 ***Other measures (medication refill adherence and continuous single- or multiple-interval measures***  
233 ***of medication gaps):*** Two studies, estimating adherence based on pharmacy refill data, reported a  
234 statistically significant difference in adherence to antidiabetic medication between people from Black  
235 and White ethnicities [27, 31]. Medication persistence was also assessed in three studies of different  
236 ethnic groups using a continuous single-interval measure of medication gaps. These studies showed  
237 that non-White ethnicity was associated with lower medication persistence when compared to White  
238 ethnicity [26, 33, 53].

239

## 240 **Study measured adherence using pill count**

241 Walker and colleagues used pill counts to assess adherence to metformin for three ethnic groups:  
242 Whites, Blacks, and Hispanics. The authors found that metformin adherence varied significantly by  
243 ethnicity, and the odds of adherence were lower for people with Black ethnicity [39].

244

## 245 **Studies measured adherence using self-report measures of adherence**

246 Eight studies assessed adherence to antidiabetic medications using a variety of self-report measures,  
247 including the five-question Medication Adherence Rating Scale [60], Morisky Medication Adherence  
248 Scale [30, 58, 63], validated Medication Compliance Questionnaire [56], Adherence to Refill and  
249 Medications Scale in Diabetes [62], medication adherence subscale of the Summary of Diabetes Self-  
250 Care Activities questionnaire[47], and self-reported scales[61]. In three of these studies, statistically  
251 significant differences in adherence were found among three Asian ethnic groups: Chinese, Malays,  
252 and Indians [56, 58, 60]. Lopez and colleagues [30] and Osborn and colleagues [47] demonstrated a  
253 significant association between increased adherence to antidiabetic medications and White ethnicity  
254 compared to other ethnic groups [30, 47]. A study conducted in the United Arab Emirates also  
255 reported significant variation in adherence levels to antidiabetic medications among three ethnic  
256 groups (Arabs of the United Arab Emirates, Arabs non-Emirate, and Asians) with the highest level of  
257 adherence reported for people with Asian ethnicity and the lowest for people with Arab ethnic  
258 groups [63]. The findings of this study are consistent with another study conducted in Qatar, in which  
259 people with diabetes of Arab ethnicity were more likely to be non-adherent to their medication  
260 compared to people from Asian ethnicity [62]. Only one study found that adherence to antidiabetic  
261 medications did not differ by ethnicity in people with type 1 diabetes [61].

262

263

## 264 Discussion

265 This systematic review aimed to examine the association between ethnicity and adherence to  
266 antidiabetic medications in people with type 1 and type 2 diabetes mellitus. This review identified  
267 several studies showing that adherence to antidiabetic medications varied according to the ethnic  
268 groups. This variation was statistically significant in 23 studies of 39 included studies and was  
269 observed when adherence was measured using various measurements methods. The finding of this  
270 review supports the work of Peeters and colleagues who reported a direct association between  
271 ethnicity and adherence across three studies [18]. This work, however, only focused on oral  
272 hypoglycemic medications in type 2 diabetes, and was published in 2011 (and since this time more

273 relevant literature has been published)[18]. Taken together, these findings may help explain some of  
274 the ethnic/racial disparities in diabetes outcomes[66-68], as optimum glycemic control is one of the  
275 major factors influencing diabetes outcome[69]. Nonetheless, these findings also offer a strong  
276 foundation for exploring the ethnicity-related factors that might explain the differences in adherence  
277 to antidiabetic medications. Understanding the possible reasons why these differences occur  
278 amongst minority ethnic groups will help develop interventions tailored to patients in ethnically  
279 diverse populations. Given the emphasis of previous literature emphasizing the need to understand  
280 patient-specific factors to design effective adherence interventions, the findings of this work are even  
281 more relevant for future research [70].

282 One interesting finding of this review is that most studies reported statistically significant differences  
283 in adherence to antidiabetic medications after controlling for different confounders (*e.g.*,  
284 socioeconomic variables) mediating the association between ethnicity and adherence to antidiabetic  
285 medications. However, the ethnicity–adherence association in some studies could be attributed to  
286 socioeconomic differences among ethnic groups, or other uncontrolled confounders, such as clinical,  
287 demographic, and psychological factors, which could mediate the ethnicity- adherence association.  
288 In accordance with the present results, one previous study demonstrated that improved health  
289 literacy diminished the ethnic differences in adherence to antidiabetic medications [47].

290 A possible explanation for the differences in adherences to antidiabetic medications among different  
291 ethnic groups after controlling confounders mediating adherence-ethnicity associations is related to  
292 the socio-cultural background and patients' beliefs and perceptions about treatment, which was  
293 shown in a systematic review of 25 cross-sectional studies to be significantly associated with  
294 medication adherence in patients with type2 diabetes, asthma, and hypertension [71]. The  
295 association may also be explained by the findings reported in several qualitative studies of the  
296 barriers of nonadherence to antidiabetic medications and diabetes self-management in some ethnic  
297 groups. For example, social stigma and cultural pressure associated with diabetes in people from  
298 South Asian background as a barrier for diabetes management [72], the preference of traditional  
299 medicines over the use of metformin in people from Māori ethnicity as a cause for suboptimal  
300 adherence [73] and feeling frustrated and fearful about taking medicines lifelong in people from



301 African American ethnicity as a reason for nonadherence[74] , are all possible explanations of the  
302 disparities. Future work could examine the socio-cultural factors affecting adherence to antidiabetic  
303 medications for different ethnic groups.

304 This review has some limitations. Firstly, it is important to acknowledge the diversity among included  
305 studies regarding the settings, designs, measurements of adherence to antidiabetic medications, and  
306 inconsistency in reporting ethnicity data. It is therefore not possible to compare across included  
307 studies to determine which ethnic group is the most adherent in the context of diabetes  
308 management. Secondly, there is no validated quality assessment tool for all observational studies,  
309 including retrospective database observational studies and cross-sectional studies. Consequently,  
310 using two critical appraisal tools does not allow for a comparison of quality across all studies. Lastly,  
311 the included studies primarily used self-reported measures or pharmacy claims data to assess  
312 adherence, leading to overestimating adherence or failing to reflect the actual medication-taking  
313 behaviour [75]. Notwithstanding these limitations, the results of this review have important  
314 implications for optimizing adherence to antidiabetic medications among different ethnic groups.  
315 Additionally, the large number of studies that met the eligibility criteria included in this review by  
316 using search strategies include broad terms with no restrictions on publication date or language, and  
317 an additional grey literature search complemented the original canvass, ensuring the inclusion of all  
318 relevant studies (S1 Text).

319

320

## 321 Conclusion

322 This systematic review is one of the first to examine the association between ethnicity and  
323 medication adherence in people with type 1 and type 2 diabetes mellitus. The findings show  
324 difference among diverse ethnic groups regarding adherence to antidiabetic medications, and these  
325 differences persist after controlling for several different demographic, clinical, socioeconomic, and  
326 psychological factors. Future research should therefore focus on explaining and understanding why  
327 these disparities occur amongst ethnic groups. Understanding the reasons behind these disparities

328 will have important implications for the future care of people with diabetes, including developing  
329 possible patient-centred interventions for optimizing adherence to diabetic therapy.

330

331

332

## 333 References

- 334 1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes  
335 prevalence for 2013 and projections for 2035. *Diabetes Res Clin Pract.* 2014;103(2):137-49.
- 336 2. Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195  
337 countries and territories: an analysis from 1990 to 2025. *Sci Rep.* 2020;10(1):14790.
- 338 3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence  
339 estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas,  
340 9(th) edition. *Diabetes Res Clin Pract.* 2019;157:107843.
- 341 4. Collaboration ERF. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *New England Journal of*  
342 *Medicine.* 2011;364(9):829-41.
- 343 5. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to  
344 2000. *Ann Intern Med.* 2007;147(3):149-55.
- 345 6. Lind M, Garcia-Rodriguez L, Booth G, Cea-Soriano L, Shah B, Ekeroth G, et al. Mortality trends in patients with  
346 and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. *Diabetologia.*  
347 2013;56(12):2601-8.
- 348 7. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and  
349 economic outcomes. *Clin Ther.* 2011;33(1):74-109.

- 350 8. Zoungas S, Chalmers J, Ninomiya T, Li Q, Cooper M, Colagiuri S, et al. Association of HbA 1c levels with vascular  
351 complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. *Diabetologia*.  
352 2012;55(3):636-43.
- 353 9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in  
354 type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the  
355 European Association for the Study of Diabetes (EASD). *Diabetes Spectrum*. 2012;25(3):154-71.
- 356 10. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications  
357 measured by claims data in patients with diabetes. *Diabetes Care*. 2004;27(12):2800-5.
- 358 11. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing  
359 and defining adherence to medications. *British journal of clinical pharmacology*. 2012;73(5):691-705.
- 360 12. De Geest S, Sabate E. Adherence to long-term therapies: evidence for action. *Eur J Cardiovasc Nurs*.  
361 2003;2(4):323.
- 362 13. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication  
363 nonadherence on hospitalization and mortality among patients with diabetes mellitus. *Arch Intern Med*.  
364 2006;166(17):1836-41.
- 365 14. Rhee MK, Slocum W, Ziemer DC, Culler SD, Cook CB, El-Kebbi IM, et al. Patient adherence improves glycemic  
366 control. *The Diabetes Educator*. 2005;31(2):240-50.
- 367 15. Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc*. 2011;86(4):304-14.
- 368 16. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. *Am J Med*. 2005;118  
369 Suppl 5A(5):27S-34S.
- 370 17. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2  
371 diabetes. *Diabetes Care*. 2003;26(5):1408-12.

- 372 18. Peeters B, Van Tongelen I, Boussery K, Mehuys E, Remon JP, Willems S. Factors associated with medication  
373 adherence to oral hypoglycaemic agents in different ethnic groups suffering from type 2 diabetes: a systematic literature  
374 review and suggestions for further research. *Diabetic Medicine*. 2011;28(3):262-75.
- 375 19. Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. *Current diabetes reports*.  
376 2013;13(6):814-23.
- 377 20. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An  
378 updated guideline for reporting systematic reviews. *Int J Surg*. 2021;88:105906.
- 379 21. Institute JB. The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews Checklist for  
380 Analytical Cross Sectional Studies. North Adelaide, Australia The Joanna Briggs Institute. 2017.
- 381 22. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance  
382 and persistence studies using retrospective databases. *Value in health*. 2007;10(1):3-12.
- 383 23. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative  
384 synthesis in systematic reviews. A product from the ESRC methods programme Version. 2006;1:b92.
- 385 24. Senior PA, Bhopal R. Ethnicity as a variable in epidemiological research. *Bmj*. 1994;309(6950):327-30.
- 386 25. Egede LE, Gebregziabher M, Hunt KJ, Axon RN, Echols C, Gilbert GE, et al. Regional, geographic, and ethnic  
387 differences in medication adherence among adults with type 2 diabetes. *Annals of Pharmacotherapy*. 2011;45(2):169-78.
- 388 26. Fernandez A, Quan J, Moffet H, Parker MM, Schillinger D, Karter AJ. Adherence to Newly Prescribed Diabetes  
389 Medications Among Insured Latino and White Patients With Diabetes. *JAMA Intern Med*. 2017;177(3):371-9.
- 390 27. Trinacty CM, Adams AS, Soumerai SB, Zhang F, Meigs JB, Piette JD, et al. Racial differences in long-term  
391 adherence to oral antidiabetic drug therapy: a longitudinal cohort study. *BMC Health Serv Res*. 2009;9:24.
- 392 28. Taira DA, Seto BK, Davis JW, Seto TB, Landsittel D, Sumida WK. Examining Factors Associated With Nonadherence  
393 And Identifying Providers Caring For Nonadherent Subgroups. *J Pharm Health Serv Res*. 2017;8(4):247-53.

- 394 29. Gatwood JD, Chisholm-Burns M, Davis R, Thomas F, Potukuchi P, Hung A, et al. Disparities in initial oral  
395 antidiabetic medication adherence among veterans with incident diabetes. *Journal of managed care & specialty*  
396 *pharmacy*. 2018;24(4):379-89.
- 397 30. Lopez JM, Bailey RA, Rupnow MF, Annunziata K. Characterization of type 2 diabetes mellitus burden by age and  
398 ethnic groups based on a nationwide survey. *Clin Ther*. 2014;36(4):494-506.
- 399 31. Adams AS, Trinacty CM, Zhang F, Kleinman K, Grant RW, Meigs JB, et al. Medication adherence and racial  
400 differences in A1C control. *Diabetes Care*. 2008;31(5):916-21.
- 401 32. Lee R, Taira DA. PEER REVIEWED: Adherence to Oral Hypoglycemic Agents in Hawaii. *Preventing chronic disease*.  
402 2005;2(2).
- 403 33. Reynolds K, An J, Wu J, Harrison TN, Wei R, Stuart B, et al. Treatment discontinuation of oral hypoglycemic agents  
404 and healthcare utilization among patients with diabetes. *Journal of Diabetes and its Complications*. 2016;30(8):1443-51.
- 405 34. Patel I, Erickson SR, Caldwell CH, Woolford SJ, Bagozzi RP, Chang J, et al. Predictors of medication adherence and  
406 persistence in Medicaid enrollees with developmental disabilities and type 2 diabetes. *Res Social Adm Pharm*.  
407 2016;12(4):592-603.
- 408 35. Marshall CJ, Rodriguez HP, Dyer W, Schmittiel JA. Racial and ethnic disparities in diabetes care quality among  
409 women of reproductive age in an integrated delivery system. *Women's Health Issues*. 2020;30(3):191-9.
- 410 36. Xie Z, St. Clair P, Goldman DP, Joyce G. Racial and ethnic disparities in medication adherence among privately  
411 insured patients in the United States. *PLoS One*. 2019;14(2):e0212117.
- 412 37. Yang Y, Thumula V, Pace PF, Banahan III BF, Wilkin NE, Lobb WB. Predictors of medication nonadherence among  
413 patients with diabetes in Medicare Part D programs: a retrospective cohort study. *Clinical therapeutics*.  
414 2009;31(10):2178-88.
- 415 38. Raebel MA, Ellis JL, Carroll NM, Bayliss EA, McGinnis B, Schroeder EB, et al. Characteristics of patients with  
416 primary non-adherence to medications for hypertension, diabetes, and lipid disorders. *J Gen Intern Med*. 2012;27(1):57-  
417 64.

- 418 39. Walker EA, Gonzalez JS, Tripputi MT, Dagogo-Jack S, Matulik MJ, Montez MG, et al. Long-term metformin  
419 adherence in the Diabetes Prevention Program Outcomes Study. *BMJ Open Diabetes Res Care*. 2020;8(1):e001537.
- 420 40. Sutton CX, Carpenter D-A, Sumida W, Taira D. 2016 Writing Contest Undergraduate Winner: The Relationship  
421 Between Medication Adherence and Total Healthcare Expenditures by Race/Ethnicity in Patients with Diabetes in Hawai  
422 'i. *Hawai'i Journal of Medicine & Public Health*. 2017;76(7):183.
- 423 41. Lo-Ciganic WH, Donohue JM, Jones BL, Perera S, Thorpe JM, Thorpe CT, et al. Trajectories of Diabetes Medication  
424 Adherence and Hospitalization Risk: A Retrospective Cohort Study in a Large State Medicaid Program. *J Gen Intern Med*.  
425 2016;31(9):1052-60.
- 426 42. Zhu VJ, Tu W, Marrero DG, Rosenman MB, Overhage JM, editors. Race and medication adherence and glycemic  
427 control: findings from an operational health information exchange. *AMIA Annual Symposium Proceedings*; 2011:  
428 American Medical Informatics Association.
- 429 43. Gebregziabher M, Lynch CP, Mueller M, Gilbert GE, Echols C, Zhao Y, et al. Using quantile regression to  
430 investigate racial disparities in medication non-adherence. *BMC medical research methodology*. 2011;11(1):1-11.
- 431 44. Shenolikar RA, Balkrishnan R, Camacho FT, Whitmire JT, Anderson RT. Race and medication adherence in  
432 Medicaid enrollees with type-2 diabetes. *J Natl Med Assoc*. 2006;98(7):1071-7.
- 433 45. Juarez DT, Tan C, Davis JW, Mau MM. Using quantile regression to assess disparities in medication adherence.  
434 *American journal of health behavior*. 2014;38(1):53-62.
- 435 46. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication  
436 adherence. *Clin Med Res*. 2013;11(2):54-65.
- 437 47. Osborn CY, Cavanaugh K, Wallston KA, Kripalani S, Elasy TA, Rothman RL, et al. Health literacy explains racial  
438 disparities in diabetes medication adherence. *J Health Commun*. 2011;16 Suppl 3(sup3):268-78.
- 439 48. Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM. Adherence to oral diabetes  
440 medications and glycemic control during and following breast cancer treatment. *Pharmacoepidemiol Drug Saf*.  
441 2015;24(1):75-85.

- 442 49. Adeyemi AO, Rascati KL, Lawson KA, Strassels SA. Adherence to oral antidiabetic medications in the pediatric  
443 population with type 2 diabetes: a retrospective database analysis. *Clin Ther.* 2012;34(3):712-9.
- 444 50. Horsburgh S, Barson D, Zeng J, Sharples K, Parkin L. Adherence to metformin monotherapy in people with type  
445 2 diabetes mellitus in New Zealand. *Diabetes Res Clin Pract.* 2019;158:107902.
- 446 51. Chepulis L, Mayo C, Morison B, Keenan R, Lao C, Paul R, et al. Metformin adherence in patients with type 2  
447 diabetes and its association with glycated haemoglobin levels. *J Prim Health Care.* 2020;12(4):318-26.
- 448 52. Kharjul MD, Cameron C, Braund R. Using the Pharmaceutical Collection Database to identify patient adherence  
449 to oral hypoglycaemic medicines. *Journal of primary health care.* 2019;11(3):265-74.
- 450 53. McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. Comparison of medication adherence and  
451 persistence in type 2 diabetes: A systematic review and meta-analysis. *Diabetes, Obesity & Metabolism.* 20(4):1040-3.
- 452 54. Langley CA, Bush J. The Aston Medication Adherence Study: mapping the adherence patterns of an inner-city  
453 population. *Int J Clin Pharm.* 2014;36(1):202-11.
- 454 55. Chong E, Wang H, King-Shier K, Quan H, Rabi D, Khan N. Prescribing patterns and adherence to medication  
455 among South-Asian, Chinese and white people with Type 2 diabetes mellitus: a population-based cohort study. *Diabetic  
456 medicine.* 2014;31(12):1586-93.
- 457 56. Abdullah NF, Khuan L, Theng CA, Sowtali SN, Juni MH. Effect of patient characteristics on medication adherence  
458 among patients with type 2 diabetes mellitus: a cross-sectional survey. *Contemporary nurse.* 2019;55(1):27-37.
- 459 57. Ying C, Shah N. Adherence to insulin treatment in children with type I diabetes mellitus at a hospital in Malaysia.  
460 *Asian J Pharm Clin Res.* 2017;10:356-61.
- 461 58. Jannoo Z, Khan NM. Medication adherence and diabetes self-care activities among patients with type 2 diabetes  
462 mellitus. *Value in health regional issues.* 2019;18:30-5.
- 463 59. Lin L-K, Sun Y, Heng BH, Chew DEK, Chong P-N. Medication adherence and glycemic control among newly  
464 diagnosed diabetes patients. *BMJ Open Diabetes Research and Care.* 2017;5(1):e000429.

- 465 60. Lee CS, Tan JHM, Sankari U, Koh YLE, Tan NC. Assessing oral medication adherence among patients with type 2  
466 diabetes mellitus treated with polytherapy in a developed Asian community: a cross-sectional study. *BMJ open*.  
467 2017;7(9):e016317.
- 468 61. Gomes MB, Negrato CA. Adherence to insulin therapeutic regimens in patients with type 1 diabetes. A  
469 nationwide survey in Brazil. *Diabetes Res Clin Pract*. 2016;120:47-55.
- 470 62. Jaam M, Mohamed Ibrahim MI, Kheir N, Hadi MA, Diab MI, Awaisu A. Assessing prevalence of and barriers to  
471 medication adherence in patients with uncontrolled diabetes attending primary healthcare clinics in Qatar. *Prim Care*  
472 *Diabetes*. 2018;12(2):116-25.
- 473 63. Mohd MMA-H, Phung H, Sun J, Morisky DE. The predictors to medication adherence among adults with diabetes  
474 in the United Arab Emirates. *Journal of Diabetes & Metabolic Disorders*. 2015;15(1):1-9.
- 475 64. Egede LE, Gebregziabher M, Hunt KJ, Axon RN, Echols C, Gilbert GE, et al. Regional, Geographic, and Ethnic  
476 Differences in Medication Adherence Among Adults with Type 2 Diabetes. *Ann Pharmacother*. 2011;45(2):169-78.
- 477 65. McGovern A, Hinton W, Calderara S, Munro N, Whyte M, de Lusignan S. A Class Comparison of Medication  
478 Persistence in People with Type 2 Diabetes: A Retrospective Observational Study. *Diabetes Ther*. 2018;9(1):229-42.
- 479 66. Goff LM. Ethnicity and Type 2 diabetes in the UK. *Diabet Med*. 2019;36(8):927-38.
- 480 67. Andersen JA, Scoggins D, Michaud T, Wan N, Wen M, Su D. Racial Disparities in Diabetes Management Outcomes:  
481 Evidence from a Remote Patient Monitoring Program for Type 2 Diabetic Patients. *Telemed J E Health*. 2021;27(1):55-61.
- 482 68. Haw JS, Shah M, Turbow S, Egeolu M, Umpierrez G. Diabetes Complications in Racial and Ethnic Minority  
483 Populations in the USA. *Curr Diab Rep*. 2021;21(1):2.
- 484 69. Khunti N, Khunti N, Khunti K. Adherence to type 2 diabetes management. *British Journal of Diabetes*.  
485 2019;19(2):99-104.
- 486 70. Williams JL, Walker RJ, Smalls BL, Campbell JA, Egede LE. Effective interventions to improve medication  
487 adherence in Type 2 diabetes: a systematic review. *Diabetes Manag (Lond)*. 2014;4(1):29-48.



- 488 71. Shahin W, Kennedy GA, Stupans I. The impact of personal and cultural beliefs on medication adherence of  
489 patients with chronic illnesses: a systematic review. *Patient Prefer Adherence*. 2019;13:1019-35.
- 490 72. Singh H, Cinnirella M, Bradley C. Support systems for and barriers to diabetes management in South Asians and  
491 Whites in the UK: qualitative study of patients' perspectives. *BMJ Open*. 2012;2(6):e001459.
- 492 73. Parkin L, Maclennan K, Te Morenga L, Inder M, Moata'ane L. What helps and hinders metformin adherence and  
493 persistence? A qualitative study exploring the views of people with type 2 diabetes. *The New Zealand Medical Journal*  
494 (Online). 2021;134(1536):25-40.
- 495 74. Shiyabola OO, Brown CM, Ward EC. "I did not want to take that medicine": African-Americans' reasons for  
496 diabetes medication nonadherence and perceived solutions for enhancing adherence. *Patient preference and adherence*.  
497 2018;12:409.
- 498 75. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence.  
499 *Medicine and pharmacy reports*. 2019;92(2):117.

500

501

## 502 Supporting information

503 [S1 Table](#). PRISMA 2020 checklist

504 [S1 Text](#). Database search terms

505 [S2 Table](#). Results of the risk of bias assessment of retrospective database studies

506 [S3 Table](#). Results of the risk of bias assessment of cross-sectional studies

507 [S4 Table](#). Data extraction form

